400 件 ・ 関連度順
概要と使いどころ
End-to-end multi-omics integration workflow. Orchestrates data harmonization, MOFA/mixOmics integration, factor interpretation, and downstream analysis across transcriptomics, proteomics, metabolomics, and other modalities. Use when integrating multiple omics datasets.
日本語の概要は準備中です。原文の説明を表示しています。
Trace drug mechanism of action — primary target → downstream signaling → pathway perturbation → tissue/organ effect → clinical outcome. Uses DrugBank, ChEMBL, KEGG, Reactome, STRING. Use for understanding how a drug works, identifying off-target effects, mechanism-based combination therapy design, and writing mechanism sections of reports.
日本語の概要は準備中です。原文の説明を表示しています。
Perform comprehensive exploratory data analysis on scientific data files across 200+ file formats. This skill should be used when analyzing any scientific data file to understand its structure, content, quality, and characteristics. Automatically detects file type and generates detailed markdown reports with format-specific analysis, quality metrics, and downstream analysis recommendations. Covers chemistry, bioinformatics, microscopy, spectroscopy, proteomics, metabolomics, and general scientific data formats.
日本語の概要は準備中です。原文の説明を表示しています。
Programmatic untargeted LC-MS feature extraction in R with the modern xcms 4.x MsExperiment/XcmsExperiment API, taking raw mzML to a feature table via CentWave peak detection, retention-time alignment, peak-density correspondence, gap-filling, CAMERA redundancy collapse, and built-in QC feature filtering. Use when converting centroided LC-MS runs into a features-by-samples matrix and deciding centWave/grouping/alignment parameters. For drift correction and QC/CV filtering execution see metabolomics/normalization-qc; for metabolite identification see metabolomics/metabolite-annotation; for the MS-DIAL GUI alternative with MS2Dec deconvolution see metabolomics/msdial-preprocessing; for downstream statistics see metabolomics/statistical-analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Turns untargeted LC-MS/MS features (m/z, RT, MS/MS) into confidence-stratified metabolite annotations using spectral-library matching (matchms), in-silico tools (SIRIUS/CSI:FingerID, MetFrag) and molecular networking, and assigns a defensible MSI/Schymanski confidence level to each. Use when naming detected features, scoring MS/MS against a reference library, running SIRIUS, or deciding what confidence level an evidence set actually supports. For upstream feature extraction see metabolomics/xcms-preprocessing and metabolomics/msdial-preprocessing; for downstream enrichment that must respect these levels see metabolomics/pathway-mapping; for lipid-specific structural annotation see metabolomics/lipidomics.
日本語の概要は準備中です。原文の説明を表示しています。
Reads, writes, and converts molecular file formats (SMILES, InChI, SDF V2000/V3000, MOL2, PDB, MMTF) using RDKit and Open Babel with rigorous handling of aromaticity perception, stereochemistry, implicit/explicit hydrogens, kekulization, and salt/fragment separation. Use when loading chemical libraries, debugging parse failures, or preparing molecules for downstream standardization, descriptor calculation, or docking.
日本語の概要は準備中です。原文の説明を表示しています。
Convert the canonical markdown+JSON deliverable of any SfSkills runtime agent into Excel, PDF, CSV, Notion card, ServiceNow ticket, or similar downstream format WITHOUT polluting the consumer's project with new dependencies or regenerating from the agent's source logic. NOT for authoring new agent output formats (use DELIVERABLE_CONTRACT.md). NOT for data-export SOQL (use bulk-api-2-patterns).
日本語の概要は準備中です。原文の説明を表示しています。
Ensure tests use clear naming and cover edge cases with proper describe/it structure.
日本語の概要は準備中です。原文の説明を表示しています。
Check whether changed code paths have corresponding tests and suggest minimal coverage.
日本語の概要は準備中です。原文の説明を表示しています。
Detects patterns that make tests flaky and proposes stabilization steps.
日本語の概要は準備中です。原文の説明を表示しています。
テストは存在するがアサーションが実質何も検証しておらず、実装が壊れても落ちない（常に PASS する）構造を diff-time で検出する。Check 1 missing assertion（テスト本体にアサーションが無い）、Check 2 tautological assertion（定数同士・入力自身・mock の戻り値自身を assert し SUT に依存しない）、Check 3 nonexistent expected literal（assertDontSee / assertNotContains 等の期待文字列が対象ファイルに実在しない）、Check 4 stale expected value（同一 diff で対象の出力が変わったのに期待値が据え置き）、Check 5 unscoped expectation（汎用的な属性・クラスを応答全体に対して assert し対象要素にスコープされていない）、Check 6 swallowed failure（例外の握り潰しや到達しない位置のアサーションで判定が成立しない）、の 6 Check を対象とする report-only。テストの有無は test-existence、未テスト経路の量は coverage-gap、非決定性は flaky-test、命名は test-naming、JS/TS の un-awaited resolves / rejects は vitest-mock-isolation、tdd-ledger artifact ベースの RED/GREEN 検証は plangate-tdd-evidence、.only / .skip / xit / @ts-ignore と空の catch は heuristic-review.mjs の決定論検出器へ委譲する
Find missing tests for critical paths, edge cases, and failure handling in changed code.
日本語の概要は準備中です。原文の説明を表示しています。
変更差分から重要なテスト観点と欠落を洗い出し、優先度付きでテストケース案を提示する
Reviews GitHub Actions workflow diffs for script injection of untrusted input, pull_request_target with untrusted checkout, over-broad GITHUB_TOKEN permissions, and unpinned third-party actions.
日本語の概要は準備中です。原文の説明を表示しています。
Think through the consequences of consequences — not just what happens immediately, but what happens next, and next after that, across time. Load when a decision looks obviously good or obviously bad on initial read, when the user is optimising for a short-term outcome that might create a long-term problem, when unintended consequences are a concern, or when deep-thinking diagnoses a second-order frame. Triggers on "what are the downstream effects", "what happens after that", "unintended consequences", "think ahead on this", "long-term vs short-term", or "what comes after that". Based on Howard Marks second-level thinking and Farnam Street mental models. Most powerful for decisions with delayed consequences or systemic effects.
日本語の概要は準備中です。原文の説明を表示しています。
Decompose tasks into structured, outcome-defined process entries with complexity triage. Load when user says "decompose this", "break this down", "what steps do I need", "plan this out", "what's the process for", "how do I approach this", or when any complex task needs structured execution planning. Includes a problem-understanding pass before complexity triage. Routes to `problem-to-plan` when the user needs planning deliverables (spec + plan + TODO). Does NOT replace brainstorming — brainstorming is design approval (upstream), this is execution planning (downstream).
日本語の概要は準備中です。原文の説明を表示しています。
Query and filter Datadog logs from the shell using the Composio CLI. Run scoped log searches, pivot across services/environments, and export structured JSON for downstream agents instead of click-driving the Datadog UI.
日本語の概要は準備中です。原文の説明を表示しています。
Segment single cells from multiplexed IMC/MIBI tissue images using Mesmer/DeepCell, Cellpose, or ilastik+CellProfiler, covering whole-cell vs nuclear segmentation, the summed-membrane-channel decision, nuclear-expansion bias, lateral spillover, resolution-floor parameters, and downstream-proxy evaluation. Use when delineating cells after preprocessing, choosing a segmentation model, building a cell mask for quantification, diagnosing impossible double-positive populations, or troubleshooting over/under-segmentation.
日本語の概要は準備中です。原文の説明を表示しています。
Identify tumor neoantigens from somatic variants with pVACtools (pVACseq/pVACfuse/pVACbind/pVACvector/pVACview) for personalized cancer vaccines and checkpoint biomarkers. Encodes the field's hard truth that binding prediction is the easy, near-solved part and single-digit-percent PPV lives downstream — so it centers clonality/CCF, HLA LOH (the silent invalidator), expression, proximal-variant phasing, agretopicity/foreignness quality, and the predicted->presented->immunogenic validation tiers. Use when nominating vaccine targets, ranking neoantigens, or building a tumor-to-candidate pipeline. Binding details in mhc-binding-prediction; ranking in immunogenicity-scoring.
日本語の概要は準備中です。原文の説明を表示しています。
Aligns sample metadata with count matrices and constructs design matrices for downstream DE, handling the alphabetical-reference-level trap (relevel BEFORE DESeq), LRT reduced-model rules, the interaction-term resultsNames trap, continuous-covariate scaling and splines, repeated measures via duplicateCorrelation or dream, high-cardinality categorical pseudo-singular designs, sample swap detection via XIST/RPS4Y1 expression and somalier/NGSCheckMate genotypes, SABV (sex-as-biological-variable) mandate, Simpson's-paradox collapsing of technical replicates, and the `~ 0 + group` parameterization for clean contrasts. Use when building a design matrix, troubleshooting reversed fold-change direction, encoding paired or repeated-measures designs, detecting sample swaps, deciding sex-as-covariate, or aggregating technical replicates.
日本語の概要は準備中です。原文の説明を表示しています。
Designs genomics experiments so technical nuisance variation (batch, lane, plate, flow cell, operator, reagent lot, processing day) is balanced against the biological variable of interest and therefore estimable rather than confounded, using constrained sample-to-batch assignment (designit, OSAT), the confounder/mediator/collider distinction, and the principle that no post-hoc correction recovers a fully confounded design. Covers detecting hidden batches with surrogate variable analysis, a decision table for downstream correction (ComBat-seq, RUVSeq, SVA) whose execution is deferred to differential-expression/batch-correction, and reproducibility metadata. Use when assigning samples to sequencing batches/lanes/plates, avoiding batch-condition confounding, deciding whether a design is salvageable by correction, choosing a correction method, or estimating the number of hidden batches. For the experimental unit, randomization, and blocking concepts see experimental-design/randomization-blocking.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes pooled CRISPR screens with MAGeCK (Li et al 2014), covering count generation (mageck count), the RRA two-condition workflow (mageck test using alpha-RRA over per-sgRNA negative-binomial p-values), the MLE multi-condition workflow (mageck mle with explicit design matrix and beta-score output), normalization choice (median vs total vs control-sgRNA vs spike-in), sgRNA efficiency injection, paired-sample testing, time-course design, drug-screen versus dropout-screen design matrices, MAGeCKFlute and MAGeCK-VISPR downstream visualization, and decision logic for when to use MAGeCK vs JACKS / BAGEL2 / drugZ / Chronos. Use when running a fresh CRISPR screen analysis, picking RRA vs MLE for the experimental design, choosing a normalization method from QC signatures, debugging MLE convergence failure or NaN beta scores, comparing MAGeCK output across tools, or building a batch-aware multi-cell-line / multi-condition MLE design matrix.
日本語の概要は準備中です。原文の説明を表示しています。
Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.
日本語の概要は準備中です。原文の説明を表示しています。
Designs and analyzes in vivo CRISPR screens in animal tumor models, organoids, and immune-cell adoptive transfers. Covers bottleneck math (250x cells/sgRNA requires ~25M cells implanted; impossible for most syngeneic models, forcing focused libraries), focused library design (Manguso 2017 Nature 547:413 immune screen; Chen 2015 tumor screens), CRISPR-StAR intrinsic-control screening (Uijttewaal 2025 Nat Biotechnol 43:1848), clonal-dynamics-limited detection, tumor-explant DNA recovery, syngeneic vs xenograft vs PDX considerations, and the relationship to downstream MAGeCK / drugZ analysis. Use when designing in vivo CRISPR screens for tumor / immune / metastasis biology, choosing focused vs genome-wide for animal models, addressing bottleneck-induced clonal collapse, picking the syngeneic / xenograft / PDX model, integrating in vivo with in vitro results, or applying CRISPR-StAR for animal experiments.
日本語の概要は準備中です。原文の説明を表示しています。